Tag Archives: cancer

Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells

March 14, 2024 by Modulight Content
No comments
Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi  Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi A new method called phototruncation-assisted cell tracking (PACT) can be used to noninvasively track migration of immune cells to understand anti-cancer immunity mechanisms. PACT is based on irreversible photo-induced truncation reaction, transforming Cy7 into Cy5 when exposed to NIR light (780 nm). PACT was used in this study to monitor spatiotemporal migration of immune cells between tumor and Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2023

December 28, 2023 by Modulight Content
No comments
Modulight Spotlights: LASER-SHARP RESEARCH – December 2023 Organic compounds are one of the leading causes of water pollution. Rhodamine 6G is a commonly used dye in the food and textile industries and can cause cancer when consumed in contaminated water. To tackle this problem, Professor T. Nyokong’s team at Rhodes University studied photocatalysis with ML7710 for degrading rhodamine, and showed increased degradation efficiency when photocatalysis was combined with ultrasound (sonocatalysis). This Laser-Sharp study offers a new method for more efficient degradation of organic pollutants for environmental Continue reading →

Light delivery optimization for H&N cancer treatment

August 30, 2021 by Modulight Content
No comments
Results Illumination with one fiber Some level of tissue heating was observed at all used light intensities. At lower intensities (60-100 mW/cm), less than 5% of the tumor was subjected to >60 ⁰C temperature, a point where irreversible thermal damage will immediately occur (photothermal ablation). At intensities of 150-200 mW/cm, 15-20% of the tumor was at >60 ⁰C temperature. At 400 mW/cm, which is FDA-recommended light irradiance for iPDT, a substantial portion of the tumor, up to 60%, was above 60 ⁰C.   Above figures Continue reading →Customer case Roswell Park Comprehensive Cancer Center was founded in 1898 as the first institute in the US devoted exclusively to cancer treatment and research. It is also the place where photodynamic therapy (PDT) was developed in the late 1970s by Thomas Dougherty. The PDT center at Roswell Park is a leader in the use of photodynamic therapy for treating different cancers. Research work includes treatment planning and light dosimetry for interstitial and intraoperative PDT to improve the quality of life and survival of cancer patients Continue reading →

Vision-sparing targeted phototherapy for uveal melanoma

July 30, 2021 by Modulight Content
No comments
Preliminary investigation of AU-011     Related Modulight products and Services   Related Publications Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Rhonda C. Kines, Cynthia D. Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks and John T. Schiller Cancer Immunology Research, 2021, 9 (6)   A Phase 1b/2 Open-label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma Prithvi Mruthyunjaya, Amy C. Schefler, Ivana K. Continue reading →Customer case Aura Biosciences, headquartered in Cambridge, MA, is developing a new class of photoactivated therapy for cancer patients together with National Cancer Institute, Emory Eye Center and Wills Eye Hospital. The therapy is based on virus-like conjugates and its primary indication is uveal melanoma. The goal is to eventually develop this technology for multiple cancer indications, such as non-muscle invasive bladder cancer (NMIBC), for which plans are underway to conduct a clinical trial. Dr. Carol Shields, MD – Aura Biosciences Dr. Rhonda Kines, PhD – Continue reading →

ML7710 for photoimmunotherapy against regulatory T cells in tumors

June 14, 2021 by Modulight Content
No comments
    Results Tumor growth was significantly suppressed by photoimmunotherapy, compared to control or IgG without light activation. Tumor growth suppression, as well as overall survival after photoimmunotherapy, were significantly better with F(ab´)2 fragments than with full IgG. This efficacy improvement might be related to killer T cells, which were detected in much higher numbers after photoimmunotherapy with F(ab´)2 fragments and are key cells for the generation of efficient systemic antitumor immunity.       Related Modulight products and Services   Related Publications The Effect Continue reading →Customer case The Laboratory of Molecular Theranostics is a major research section of the Molecular Imaging Program at National Cancer Institute (NCI) and is led by Dr. Hisataka Kobayashi. The groundbreaking research includes the development of imaging and theranostic probes, which can aid in cancer detection and treatment. Dr. Kobayashi has invented near-infrared photoimmunotherapy (NIR-PIT) with IRDye700DX, which is currently in FDA-designated fast-track Phase 3 trials for inoperable Head & Neck cancer. Dr. Hisataka Kobayashi M.D., PhD   Dr. Peter L. Choyke M.D., PhD   Continue reading →

ML7710 for fluorescence imaging: Detection of colorectal polyps in humans using c-Met targeted fluorescent peptide

May 4, 2021 by Modulight Content
No comments
Motivation for the study Polyps are small growths on the inner lining of the colon or rectum, affecting around 1 in 4 people over the age of 50. Certain types of polyps may eventually become cancerous, and colon cancer prevention relies on colonoscopy using white light to detect and remove the polyps. However, small and flat polyps are difficult to detect and frequently missed with this technique. More precise methods to detect polyps before they progress to colorectal cancer are urgently needed. GE Healthcare’s patented EMI-137 Continue reading →Customer Case Research by: GE Healthcare is a manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals, R&D collaborations with Leiden University MC for early detection of colorectal tumors. Modulight products: ML7710 series clinical laser system (635 nm, 3 W) Laser use: Clinical single-wavelength laser device used for exciting novel fluorescence probe used to detect colorectal polyps. Link to the study: Dr. James Hardwick, Professor of gastroenterology & hepatology Research topics: Professor Hardwick’s research has contributed to many key improvements in the detection and treatment of colorectal Continue reading →

Oncology

April 20, 2021 by Modulight Content
No comments
Modulight lasers in oncology Cancer touches almost all people worldwide - either personally or through someone you know. The treatment options for cancer are much better than a couple of decades ago but cancer still remains a leading cause of death killing 10 million people annually. Modulight participates in the fight against cancer by providing innovative clinical laser solutions for different laser-assisted therapies.  Since 2010, Modulight has offered complete medical laser systems for oncology professionals, and today these systems are equipped with state-of-the-art features like Continue reading →

Theranostic Prospects of Graphene Quantum Dots in Breast Cancer

October 26, 2020 by Modulight
No comments
Published in: ACS Biomaterials Science and Engineering Authors: Rahul S. Tade, Pravin O. Patil  Published in: ACS Biomaterials Science and Engineering Authors: Rahul S. Tade, Pravin O. Patil   Breast cancer (BC) is increasing as a significant cause of mortality among women. In this context, early diagnosis and treatment strategies for BC are being developed by researchers at the cellular level using advanced nanomaterials. However, immaculate etiquette is the prerequisite for their implementation in clinical practice. Considering the stolid nature of cancer, combining diagnosis and therapy (theranostics) using graphene quantum dots (GQDs) is a prime focus and challenge for Continue reading →

Breaking the selectivity‑uptake trade‑off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi‑tier cancer targeting

January 2, 2020 by Modulight
No comments
Published in: Journal of Nanobiotechnology Authors: Barry J. Liang, Michael Pigula, Yan Baglo, Daniel Najafali , Tayyaba Hasan, Huang‑Chiao Huang    Published in: Journal of Nanobiotechnology Authors: Barry J. Liang, Michael Pigula, Yan Baglo, Daniel Najafali , Tayyaba Hasan, Huang‑Chiao Huang   The ML6600 laser was used to test the PDT efficacy of a novel photoimmunoconjugate-nanoliposome (PIC-Nal) comprising of EGFR-targeted Cetuximab, BPD photosensitizer and irinotecan chemoterapy inside a liposome. Different cancer cell lines were used and cell viability was determined after PDT.   Read the article here

Photodynamic Therapy of Non–Small Cell Lung Cancer. Narrative Review and Future Directions

February 1, 2016 by Modulight
No comments
Published in: Annals of the American Thoracic Society Authors: Gal Shafirstein 1,2, Athar Battoo 3, Kassem Harris 4, Heinz Baumann 5, Sandra O. Gollnick 1,6, Joerg Lindenmann 1,7, and Chukwumere E. Nwogu 3 1Photodynamic Therapy Center 2Department of Cell Stress Biology 3Department of Thoracic Surgery 4Department of Medicine, Interventional Pulmonology 5Department of Molecular and Cellular Biology, and 6Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York; and 7Division of Thoracic and Hyperbaric Surgery, Medical University Graz, Graz, Austria Corresponding Author: Gal Shafirstein    Published in: Annals of the American Thoracic Society Authors: Gal Shafirstein 1,2, Athar Battoo 3, Kassem Harris 4, Heinz Baumann 5, Sandra O. Gollnick 1,6, Joerg Lindenmann 1,7, and Chukwumere E. Nwogu 3 1Photodynamic Therapy Center 2Department of Cell Stress Biology 3Department of Thoracic Surgery 4Department of Medicine, Interventional Pulmonology 5Department of Molecular and Cellular Biology, and 6Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York; and 7Division of Thoracic and Hyperbaric Surgery, Medical University Graz, Graz, Austria Corresponding Author: Gal Shafirstein     The paper describes the history of lung cancer PDT and results from relevant studies. Continue reading →